CoChat
Sign Up
Cited by 20Mesenchymal stem cell researchLiver Disease and TransplantationLiver physiology and pathology

The DOI matches its Crossref record; the references it cites are not checked yet.

Therapeutic efficacy and safety of umbilical cord mesenchymal stem cell transplantation for liver cirrhosis in Chinese population: A meta-analysis

Sang, Weiwei, Lv, Benji, Li, Ke, Lu, Yan·2018·Clinics and Research in Hepatology and Gastroenterology
DOI 10.1016/j.clinre.2017.11.003
Open this paper in CoChat — free account

Abstract

Background and objective Mesenchymal stem cells transfusion has been considered as a promising option for liver cirrhosis (LC). The aim of this study was to systematically evaluate the efficacy and safety of umbilical cord mesenchymal stem cells (UMSC) combined with traditional supportive therapy (TST) for the treatment of patients with LC. Methods Data was extracted from clinical trials published on Web of Science, PubMed, EMBASE, Cochrane Library, Wanfang and CNKI database. The evaluated outcome measurements included liver function, coagulation function, liver fibrosis indexes, clinical symptoms, quality of life (QOL) and adverse events. Results A total of 14 trials including 717 LC patients met our selection criteria were involved. The liver function of LC patients was significantly improved after combined therapy (UMSC plus TST), indicated by decreased total bilirubin, alanine aminotransferase and prothrombin time, and increased serum albumin, cholinesterase and prothrombin activity. The QOL of patients was also improved after UMSC therapy. Compared with TST alone, the combined therapy showed better treatment effect based on measurements of hyaluronic acid (OR=-143.20, CI=-181.58 to -104.82, P<0.00001), laminin (OR=-50.65, CI=-53.70 to -47.61, P<0.00001), type III procollagen (OR=-8.68, CI=-9.00 to -8.36, P<0.00001), type IV collagen (OR=-105.79, CI=-132.44 to -79.14, P<0.00001) and plasma prolidase (OR=-876.54, CI=-911.89 to -840.56, P<0.00001). Moreover, the patients' clinical symptoms including fatigue (4th, P=0.003; 8th, P=0.01), appetite (4th, P<0.0001; 8th, P=0.06), ascites (4th, P=0.03; 8th, P=0.17), and abdominal distension (4th, P=0.0008; 8th, P=0.64) were also improved in patients treated by combined therapy without adverse events observed. Conclusion UMSC and TST combined therapy for LC patients improved their liver function, clinical symptoms and QOL without severe adverse events, therefore is safe and effective in LC therapy.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.clinre.2017.11.003

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists haven’t been fetched yet

References 37 · Cited by 20

Research works printed but not linked: 43

  1. Irfan, 2015, Could stem cell therapy be the cure in liver cirrhosis?, J Clini Exp Hepatol, 5, 142, 10.1016/j.jceh.2014.03.042 · DOI
  2. Than, 2016, Clinical effectiveness of cell therapies in patients with chronic liver disease and acute-on-chronic liver failure: a systematic review protocol, Syst Rev, 5, 100, 10.1186/s13643-016-0277-6 · DOI
  3. Ma, 2015, Transplantation of autologous mesenchymal stem cells for end-stage liver cirrhosis: a meta-analysis based on seven controlled trials, Gastroenterol Res Pract, 2015, 1
  4. Pan, 2014, Bone marrow-derived mesenchymal stem cell therapy for decompensated liver cirrhosis: a meta-analysis, World J Gastroenterol, 20, 14051, 10.3748/wjg.v20.i38.14051 · DOI
  5. Habeeb, 2015, Hepatic stem cells: a viable approach for the treatment of liver cirrhosis, World J Stem Cells, 7, 859, 10.4252/wjsc.v7.i5.859 · DOI
  6. Qi, 2015, Clinical outcomes of the transplantation of stem cells from various human tissue sources in the management of liver cirrhosis: a systematic review and meta-analysis, Curr Stem Cell Res Ther, 10, 166, 10.2174/1574888X09666141112114011 · DOI
  7. Lanthier, 2017, Autologous bone marrow-derived cell transplantation in decompensated alcoholic liver disease: what is the impact on liver histology and gene expression patterns?, Stem Cell Res Ther, 8, 88, 10.1186/s13287-017-0541-2 · DOI
  8. Salama, 2014, Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease, Stem Cell Res Ther, 5, 70, 10.1186/scrt459 · DOI
  9. Jang, 2014, Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study, Liver Int, 34, 33, 10.1111/liv.12218 · DOI
  10. Mohamadnejad, 2013, Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis, Liver Int, 33, 1490, 10.1111/liv.12228 · DOI · Paper page
  11. Zhou, 2011, Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes, Cell Immunol, 272, 33, 10.1016/j.cellimm.2011.09.010 · DOI
  12. Mohamadnejad, 2007, Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis, Arch Iran Med, 10, 459
  13. Beane, 2014, Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells, PLoS One, 9, e115963, 10.1371/journal.pone.0115963 · DOI
  14. Zhang, 2012, Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients, J Gastroenterol Hepatol, 27Suppl2, 112, 10.1111/j.1440-1746.2011.07024.x · DOI · Paper page
  15. Nagamura-Inoue, 2016, Umbilical cord is a rich source of mesenchymal stromal cells for cell therapy, Curr Stem Cell Res Ther, 11, 634, 10.2174/1574888X10666151026115017 · DOI
  16. Lin, 2012, [Prospective controlled trial of safety of human umbilical cord derived-mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis], Zhonghua Gan Zang Bing Za Zhi, 20, 487
  17. Wang, 2013, Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis, J Gastroenterol Hepatol, 28Suppl1, 85, 10.1111/jgh.12029 · DOI · Paper page
  18. Du, 2011, Effect of human umbilical cord mesenchymal stem cell hepatic artery transplantation on serum PA and CHE in patients with decompensated cirrhosis, Shandong Med J, 51, 59
  19. Gong, 2014, Human umbilical cord blood MSCs transplantation in treatment of decompensated liver cirrhosis, Chin Gen Pract, 17, 2392
  20. He, 2010, Short-term effect effect of human umbilical cord mesenchymal stem cell hepatic artery transplantation on liver fibrosis index in patients with end-stage liver cirrhosis, Hainan Med J l, 21, 26
  21. Ji, 2017, Effects of human umbilical cord mesenchymal stem cells combined with biejia ruangan tablets for treatment of decompensated hepatitis B cirrhosis, J Clin Res, 34, 178
  22. Luo, 2016, Effect of human umbilical cord mesenchymal stem cell adjuvant therapy on liver function and fibrosis indicators as well as the degree of inflammation in patients with hepatitis B cirrhosis, J Hainan Med Univ, 22, 1069
  23. Luo, 2015, Efficacy observation of mesenchymal stem cells derived from human umbilical cord for therapy of hepatitis B patients with decompensated cirrhosis, Chin J Exp Clin Virol, 29, 239
  24. Sun, 2012, Impact of UC-MSC therapy on the quality of life of patients with HBV-related liver cirrhosis, J Qilu Nurs, 18, 8
  25. Sun, 2016, Observation clinical effect of navel-applied plaster and colon dialysis combined with huc-MSCs to treat refractory ascites of cirrhosis, China Med Herald, 13, 4
  26. Tong, 2015, Therapeutic effect of human umbilical cord mesenchymal stem cell transplantation via peripheral vein on decompensated cirrhosis, World Chin J Digestol, 23, 2457, 10.11569/wcjd.v23.i15.2457 · DOI
  27. Zhang, 2017, Therapeutic effect of human umbilical cord mesenchymal stem cells transplantation via peripheral vein in the treatment of hepatitis B liver cirrhosis, J Hebei Med Univ, 38, 270
  28. Zhang, 2012, Short-term effects of human umbilical cord-derived mesenchymal stem cells in treatment of patients with decompensated cirrhosis, Chin J Tissue Eng Res, 16, 2585
  29. Zeng, 2015, Umbilical cord mesenchymal stem cells with bone marrow stem cells in the treatment of decompensated cirrhosis: a 1-year follow-up study, Chin J Tissue Eng Res, 19, 1533
  30. Zhu, 2013, Curative effect of human umbilical cord mesenchymal stem cells on patients with decompensated cirrhosis, J Zhengzhou Univ, 48, 117
  31. Zhang, 2013, Stem cell therapies for liver failure and cirrhosis, J Hepatol, 59, 183, 10.1016/j.jhep.2013.01.018 · DOI
  32. van Poll, 2008, Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo, Hepatology, 47, 1634, 10.1002/hep.22236 · DOI · Paper page
  33. Parekkadan, 2007, Yarmush. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells, Biochem Biophys Res Commun, 363, 247, 10.1016/j.bbrc.2007.05.150 · DOI
  34. Parekkadan, 2007, Yarmush. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure, PLoS One, 2, e941, 10.1371/journal.pone.0000941 · DOI
  35. Abdel Aziz, 2007, Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis, Clin Biochem, 40, 893, 10.1016/j.clinbiochem.2007.04.017 · DOI
  36. Oyagi, 2006, Therapeutic effect of transplanting HGF-treated bone marrow mesenchymal cells into CCl4-injured rats, J Hepatol, 44, 742, 10.1016/j.jhep.2005.10.026 · DOI
  37. Wang, 1998, [Correlation of serum markers with fibrosis staging in chronic viral hepatitis], Zhonghua Bing Li Xue Za Zhi, 27, 185
  38. Yubo, 2017, Clinical efficacy and safety of mesenchymal stem cell transplantation for osteoarthritis treatment: a meta-analysis, PLoS One, 12, e0175449, 10.1371/journal.pone.0175449 · DOI
  39. Lalu, 2012, Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials, PLoS One, 7, e47559, 10.1371/journal.pone.0047559 · DOI
  40. Wang, 2014, Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study, Arthritis Res Ther, 16, R79, 10.1186/ar4520 · DOI
  41. Chen, 2016, Efficacy of umbilical cord-derived mesenchymal stem cell-based therapy for osteonecrosis of the femoral head: a three-year follow-up study, Mol Med Rep, 14, 4209, 10.3892/mmr.2016.5745 · DOI
  42. Li, 2014, The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis, Cell Transplant, 23Suppl1, S113, 10.3727/096368914X685005 · DOI
  43. Zhao, 2015, Clinical observation of umbilical cord mesenchymal stem cell treatment of severe systolic heart failure, Genet Mol Res, 14, 3010, 10.4238/2015.April.10.11 · DOI

Metadata

Authors
Sang, W., Lv, B., Li, K., & Lu, Y.
Affiliations
Taishan Medical University (CN)
ORCID
Li, Ke
Venue
Clinics and Research in Hepatology and Gastroenterology
Publisher
Elsevier BV
Published
2018-06
Volume
42
Issue
3
Pages
193-204
ISSN
2210-7401 (ISSN-L)
DOI
10.1016/j.clinre.2017.11.003
OpenAlex
W2774589611
Cited by
20
References
37
Citations by year
2026: 1 · 2025: 3 · 2024: 3 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 4 · 2018: 1
FWCI
0.31
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Clinics and Research in Hepatology and Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
human umbilical cord mesenchymal stem cells, liver cirrhosis, stem cell transplantation, liver function, liver fibrosis, quality of life, adverse events, hyaluronic acid, laminin, type IV collagen, type III procollagen, Chinese patients, treatment efficacy and safety, ascites, fatigue
MeSH terms
China, Humans, Liver Cirrhosis, Treatment Outcome, Cord Blood Stem Cell Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review